2020
DOI: 10.1292/jvms.19-0560
|View full text |Cite
|
Sign up to set email alerts
|

Comparison of the efficacy of cyclosporine and leflunomide in treating inflammatory colorectal polyps in miniature dachshunds

Abstract: Inflammatory colorectal polyps (ICRPs) are frequently observed in miniature dachshunds in Japan and treated by prednisolone and immunosuppressive drugs such as cyclosporine and leflunomide. The purpose of this retrospective study was to compare the treatment efficacy, such as response rate, response interval, recurrence rate, and adverse events between cyclosporine and leflunomide. While the response rates were significantly higher in dogs treated with leflunomide, no significant differences were observed in t… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
2
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(2 citation statements)
references
References 14 publications
0
2
0
Order By: Relevance
“…Reports of leflunomide to treat immune‐mediated diseases in dogs are limited to a few case series including dogs with immune‐mediated polyarthritis (IMPA), inflammatory colorectal polyps, immune‐mediated haemolytic anaemia (IMHA), canine reactive histiocytosis, erosive IMPA and Evans' Syndrome (Affolter & Moore, 2000; Bianco & Hardy, 2009; Colopy et al., 2010; Fukushima et al., 2016; Gregory et al., 1998; Sato et al., 2017; Shaughnessy et al., 2016; Tani et al., 2020; Weingart et al., 2019). In total, 21 dogs with naITP treated with leflunomide are reported in literature at the time of writing (Gregory et al., 1998; Sato et al., 2017; Scuderi et al., 2016).…”
Section: Introductionmentioning
confidence: 99%
“…Reports of leflunomide to treat immune‐mediated diseases in dogs are limited to a few case series including dogs with immune‐mediated polyarthritis (IMPA), inflammatory colorectal polyps, immune‐mediated haemolytic anaemia (IMHA), canine reactive histiocytosis, erosive IMPA and Evans' Syndrome (Affolter & Moore, 2000; Bianco & Hardy, 2009; Colopy et al., 2010; Fukushima et al., 2016; Gregory et al., 1998; Sato et al., 2017; Shaughnessy et al., 2016; Tani et al., 2020; Weingart et al., 2019). In total, 21 dogs with naITP treated with leflunomide are reported in literature at the time of writing (Gregory et al., 1998; Sato et al., 2017; Scuderi et al., 2016).…”
Section: Introductionmentioning
confidence: 99%
“…6 The primary metabolite of leflunomide (A77-1726) inhibits pyrimidine synthesis through reversible selective inhibition of dihydroorotate dehydrogenase and subsequent inhibition of activated B and T lymphocytes resulting in dampened proinflammatory signaling and reduced neutrophil infiltration. 1,[7][8][9][10][11][12][13][14] Leflunomide's efficacy for management of rheumatoid arthritis is comparable to methotrexate with respect to improved clinical signs and slowing progression of joint damage. 15 Although largely tolerated, adverse effects reported in people include diarrhea, liver enzyme elevation (2% to 13% of patients), nausea, headaches, skin rashes, alopecia, epidermal necrosis, myelosuppression, and interstitial lung disease.…”
mentioning
confidence: 99%